NASDAQ · ACB
Healthcare · Drug Manufacturers - Specialty & Generic
$4.08
Down-$0.07 (-1.69%)
Updated Oct 29, 2026, 1:05 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
ACB closed at $4.08 after 21 trading sessions, up 4.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $4.09 | $4.10 | $3.985 | $4.08 | 555.46K |
| Oct 27, 2026 | $3.90 | $4.155 | $3.90 | $4.15 | 579.16K |
| Oct 26, 2026 | $3.85 | $3.95 | $3.84 | $3.90 | 494.67K |
| Oct 23, 2026 | $3.96 | $3.96 | $3.87 | $3.88 | 602.88K |
| Oct 22, 2026 | $3.93 | $4.06 | $3.90 | $3.97 | 683.4K |
| Oct 21, 2026 | $3.98 | $4.09 | $3.92 | $3.96 | 821.3K |
| Oct 20, 2026 | $3.90 | $4.06 | $3.90 | $3.97 | 654.31K |
| Oct 19, 2026 | $4.00 | $4.09 | $3.96 | $3.96 | 617.77K |
| Oct 16, 2026 | $4.11 | $4.12 | $3.98 | $3.99 | 995.32K |
| Oct 15, 2026 | $4.15 | $4.2251 | $4.08 | $4.10 | 891.67K |
| Oct 14, 2026 | $4.21 | $4.31 | $4.13 | $4.17 | 1.19M |
| Oct 13, 2026 | $4.25 | $4.34 | $4.24 | $4.29 | 650.2K |
| Oct 12, 2026 | $4.51 | $4.55 | $4.29 | $4.35 | 603.94K |
| Oct 9, 2026 | $4.41 | $4.575 | $4.40 | $4.49 | 1.35M |
| Oct 8, 2026 | $4.45 | $4.50 | $4.37 | $4.43 | 1.47M |
| Oct 7, 2026 | $4.59 | $4.67 | $4.44 | $4.46 | 1.38M |
| Oct 6, 2026 | $4.58 | $4.64 | $4.40 | $4.59 | 1.94M |
| Oct 5, 2026 | $4.37 | $4.65 | $4.30 | $4.46 | 4.63M |
| Oct 2, 2026 | $3.94 | $3.97 | $3.865 | $3.92 | 682.85K |
| Oct 1, 2026 | $3.87 | $3.9499 | $3.845 | $3.90 | 607.48K |
| Sep 30, 2026 | $4.01 | $4.02 | $3.815 | $3.90 | 1.61M |
The latest Smart Investors Daily articles mentioning ACB.
Company
Market Activity
Research & News
ACB research
Company profile and research snapshot.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | ATB CAPITAL MARKETS | Outperform | — |
| Aug 18, 2026 | TD COWEN | Buy | — |
| Aug 5, 2026 | ROTH CAPITAL PARTNERS | Neutral | — |
| Aug 5, 2026 | CANACCORD GENUITY | Buy | — |
| Aug 5, 2026 | ZUANIC & ASSOCIATES | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Curaleaf raised its hostile bid for Aurora Cannabis to about $5 per share, citing a 217% ex-cash premium, as the two cannabis firms clash over board access and valuation.
Yahoo · Oct 19, 2026
Curaleaf Holding first approached Aurora about a friendly merger, and after it was rejected, launched a hostile bid.
Benzinga · Oct 19, 2026
Curaleaf condemns Aurora Cannabis for rejecting its enhanced proposal, accusing the board of obstructing engagement and fair value.
Yahoo · Oct 19, 2026
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s ("Aurora") Notice of Change to its directors' circular, dated October 14, 2026, in which Aurora's Board again recommended that shareholders reject Curaleaf's enhanced proposal.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACB.
